logo
Tianjin ZX USD Stock (T14) - Price and Fundamental Data | DZHI - DZH International
Tianjin ZX USD (T14)

Company Info and Fundamentals

Principal Activities
The Group's businesses cover a wide range of products including Chinese patent medicine, Chinese medicinal drinks, Chinese medicinal raw materials, biotechnology medicine, chemical raw material medicine and preparations, and nutritional and health products. It has over 800 medicinal products in over 20 types of formulations. The main products are Suxiao Jiuxin pill (used for treatment of heart disease), Huoxiang Zhengqi Soft capsule (used for treatment of intestines and stomach disease), Gengnian An (used for treatment of menopause symptoms), Zi Long Jin tablet (used for treatment of cancer), Xuefu Zhuyu capsule (used for treatment of diseases relating to heart and head blood vessel), Biqi capsule (used for treatment of rheumatism), Anfulong a-2b Interferon (used for increasing immunity ), Ge Lie Qi Te (used for treatment of diabetes), and Te Zi She Fu (used for diminishing inflammation).
Profile
Full NameTianjin ZhongXin Pharmaceuticals Group CStock NoT14
ExchangeSingapore Exchange (SGX)BoardMain board
ISIN CodeCNE100000924Year-End31-Dec
Exchange SectorManufacturingSub SectorPharmaceuticals
Par Value (CNY)1.0000Issued Shares (Mil)768.8730
Paid-Up Cap. (CNY Mil)768.8730Market Capitalization (Mil)626.6315
Technical
Share Price (USD)
Current Price0.81
Previous Close0.81
Week High0.95
Week Low0.76
Month High0.95
Month Low0.76
52-week High1.18
52-week Low0.76
Share Price Performance(%)
MTD change1.8868
YTD change-4.7059
Volume
Today Volume('000)20
100-day Average Daily Volume ('000)289.44
Technical Indicators-A shapshot
RSI47.40
100-day Moving average0.87
Ratio (Daily)
Dividend Yield24.54
P/E ratio1.12



Financial Ratios
201820172016
CurrencyRMBRMBRMB
Exchange Rate*---
Profitability Ratio
Return on Equity11.40010.63410.127
Return on Revenue8.8338.3686.786
Liquidity Ratio
Return on Equity2.4972.1282.009
Return on Revenue1.8031.5341.537
Gross Eps (cents) *73.00062.00055.000
Dividend (cents) *20.00015.00025.000
Net tangible asset0.2860.4010.426
Price to cash flow ratio1.837-44.1351.605
Cash for per share0.441-0.0180.505
Price to book ratio0.1230.1350.143
* Calculation is based on the specific Currency Exchange Rate
Financial Ratios
2019 Q22019 Q12018 Q42018 Q3
CurrencyRMBRMBRMB
Exchange Rate*----
Profitability Ratio
Return on Equity6.7913.70811.4008.562
Return on Revenue9.81610.8368.8338.594
Liquidity Ratio
Return on Equity2.2792.7302.4972.199
Return on Revenue1.6642.0091.8031.632
Gross Eps (cents) *0.4500.2500.7300.520
Dividend (cents) *0.0000.0000.0000.000
Net tangible asset0.2930.2550.2860.324
Price to cash flow ratio4.1555.5881.8371.950
Cash for per share0.1950.1450.4410.415
Price to book ratio0.1190.1140.1230.129
* Calculation is based on the specific Currency Exchange Rate
No Data Avaliable
Historical Prices
OpenHighLowCloseVol('000)O/C RangeH/L Range
2019-09-200.820.820.810.8120-0.000.00
2019-09-190.820.820.810.8169-0.010.01
2019-09-180.820.830.820.83310.010.01
2019-09-170.820.820.820.82340.000.00
2019-09-160.820.830.820.83710.010.01
2019-09-130.830.830.830.831680.010.01
2019-09-120.810.830.810.836030.010.01
2019-09-110.810.810.810.811240.000.00
2019-09-100.810.820.810.811350.000.01
2019-09-090.810.820.810.81182-0.010.01
2019-09-060.810.820.810.812440.010.01
2019-09-050.810.810.810.8169-0.010.01
2019-09-040.800.820.800.811350.010.01
2019-09-030.800.800.800.8040.000.00
2019-09-020.800.810.800.80820.000.01
2019-08-300.810.810.800.80181-0.010.02
2019-08-290.800.810.800.81820.010.01
2019-08-280.810.810.800.80113-0.010.01
2019-08-270.830.830.810.82142-0.010.01
2019-08-260.810.840.810.843190.020.03
2019-08-230.830.840.830.83175-0.010.01
2019-08-220.830.840.830.84300.010.01
2019-08-210.820.840.820.831550.010.02
Time and Sales
TypeLast DoneChangeVolume ('000)
TotalChange
17:04:26Buy Up0.810-0.00510.00.0
14:33:33Buy Up0.8150.81510.010.0